Loss of membranous Ep-CAM in budding colorectal carcinoma cells

Modern Pathology

Volumn 20, Issue 2, 2007, Pages 221-232

  Gosens, Marleen J E M ^a   Van Kempen, Léon C L ^a   Van De Velde, Cornelis J H ^b   Van Krieken, J Han J M ^a   Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adhesion; Budding; Colorectal cancer; Ep CAM; Recurrence; Tumor front

Indexed keywords

BETA CATENIN; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CARCINOMA CELL; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL NUCLEUS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRACELLULAR TRANSPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TRANSPORT; RECTUM CANCER; RECURRENCE RISK; STAINING; TUMOR VOLUME;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BETA CATENIN; CELL ADHESION; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NETHERLANDS; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33947283773     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800733     Document Type: Article

References (40)

1. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-635.
2. Masaki T, Muto T. Predictive value of histology at the invasive margin in the prognosis of early invasive colorectal carcinoma. J Gastroenterol 2000;35:195-200.
3. Brabletz T, Jung A, Hermann K, et al. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998;194:701-704.
4. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-59.
5. Masaki T, Goto A, Sugiyama M, et al. Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 2001;92:2539-2546.
6. Appella E, Weber IT, Blasi F. Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett 1988;231:1-4.
7. Balzar M, Bakker HA, Briaire-de-Bruijn IH, et al. Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Mol Cell Biol 1998;18:4833-4843.
8. Tsubura A, Senzaki H, Sasaki M, et al. Immunohistochemical demonstration of breast-derived and/or carcinoma-associated glycoproteins in normal skin appendages and their tumors. J Cutan Pathol 1992;19:73-79.
9. Cirulli V, Crisa L, Beattie GM, et al. KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 1998;140:1519-1534.
10. Kasper M, Behrens J, Schuh D, et al. Distribution of E-cadherin and Ep-CAM in the human lung during development and after injury. Histochem Cell Biol 1995;103:281-286.
11. Momburg F, Moldenhauer G, Hammerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-2891.
12. Winter MJ, Nagtegaal ID, van Krieken JH, et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003;163:2139-2148.
13. Salem RR, Wolf BC, Sears HF, et al. Expression of colorectal carcinoma-associated antigens in colonic polyps. J Surg Res 1993;55:249-255.
14. Packeisen J, Kaup-Franzen C, Knieriem HJ. Detection of surface antigen 17-1A in breast and colorectal cancer. Hybridoma 1999;18:37-40.
15. Basak S, Speicher D, Eck S, et al. Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 1998;90:691-697.
16. van Kempen LC, Rijntjes J, Claes A, et al. Type I collagen synthesis parallels the conversion of keratinocytic intraepidermal neoplasia to cutaneous squamous cell carcinoma. J Pathol 2004;204:333-339.
17. Kapiteijn E, Meershoek-Klein Kranenbarg E, Steup WH, et al. Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg 1999;165:410-420.
18. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
19. Nagtegaal ID, Meershoek-Klein Kranenbarg E, Hermans J, et al. Pathology data in the central databases of multicenter randomized trials need to be based on pathology reports and controlled by trained quality managers. J Clin Oncol 2000;18:1771-1779.
20. Nagtegaal ID, Marijnen CA, Meershoek-Klein Kranenbarg E, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study. BMC Cancer 2001;1:7.
21. Sobin LH, Wittekind C (eds). UICC TNM Classification of Malignant Tumors, 5th edn. John Wiley & Sons, Inc.: New York, 1997, pp 66-69.
22. Blenkinsopp WK, Stewart-Brown S, Blesovsky L, et al. Histopathology reporting in large bowel cancer. J Clin Pathol 1981;34:509-513.
23. Ueno H, Jones AM, Wilkinson KH, et al. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut 2004;53:581-586.
24. Ueno H, Price AB, Wilkinson KH, et al. A new prognostic staging system for rectal cancer. Ann Surg 2004;240:832-839.
25. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
26. Losi L, Ponti G, Gregorio CD, et al. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006;202:663-670.
27. Masaki T, Matsuoka H, Sugiyama M, et al. Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol 2006;21:1115-1121.
28. Greenwald I, Rubin GM. Making a difference: the role of cell-cell interactions in establishing separate identities for equivalent cells. Cell 1992;68:271-281.
29. Hayashida Y, Honda K, Idogawa M, et al. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res 2005;65:8836-8845.
30. Honda K, Yamada T, Hayashida Y, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005;128:51-62.
31. Litvinov SV, Bakker HA, Gourevitch MM, et al. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994;2:417-428.
32. Brabletz T, Jung A, Dag S, et al. Beta-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-1038.
33. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
34. Takahashi M, Tsunoda T, Seiki M, et al. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002;21:5861-5867.
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
36. Horkko TT, Klintrup K, Makinen JM, et al. Budding invasive margin and prognosis in colorectal cancer - no direct association with beta-catenin expression. Eur J Cancer 2006;42:964-971.
37. Punt CJ, Nagy A, Douillard JY, et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-677.
38. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-1183.
39. Sears HF, Atkinson B, Mattis J, et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982;1:762-765.
40. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-1442.